TAG:
medical laboratory testing
What’s New at Theranos? Lab Firm Expands in AZ
By Robert Michel | From the Volume XXII No. 6 – April 20, 2015 Issue
CEO SUMMARY: Over the past 18 months, Theranos has taken steps to enter the clinical lab marketplace. Across Greater Phoenix, Theranos now has specimen collection centers in about 40 Walgreens pharmacies. It is opening a CLIA lab facility in Scottsdale. Now that it is delivering…
My Visit to Walgreens for Theranos Lab Tests
By Robert Michel | From the Volume XXI No. 11 – August 11, 2014 Issue
CEO SUMMARY: One of the biggest unknowns in the lab testing industry today is Theranos, the lab testing company based in Palo Alto, California. It says its proprietary technology is poised to transform the lab testing experience for patients and physicians. It says it can perform hundreds…
Lab Copay on the Table, But for Now, It’s Australia
By Robert Michel | From the Volume XXI No. 9 – June 30, 2014 Issue
CEO SUMMARY: Patient copayment is the idea that always appeals to government health officials who want to control healthcare costs. In Australia, Parliament has yet to vote on a bill that would, starting in July 2015, institute a patient copayment of $7.00 Australian for …
Across the Pond, Lots of Changes in Lab Testing
By R. Lewis Dark | From the Volume XXI No. 2 – February 3, 2014 Issue
IN BOTH THE UNITED KINGDOM AND EUROPE, plenty of change is unfolding in clinical laboratory and anatomic pathology testing. Our intrepid Editor-in-Chief, Robert L. Michel, spent last week in England attending our annual Frontiers in Laboratory Medicine conference, now in its eleventh year. …
Theranos Won’t Discuss Disruptive Lab Technology
By Joseph Burns | From the Volume XX No. 13 – September 30, 2013 Issue
CEO SUMMARY: In a partnership with Walgreens pharmacies, Theranos Inc. announced that it will run clinical lab tests on “micro-samples” and collect these blood samples without venipuncture. Even as Theranos touts the patient-friendly benefits of its proprietary diagnostic technology, …
CMS’ Proposed Lab Rules May Not Fly with Congress
By Joseph Burns | From the Volume XX No. 12 – September 9, 2013 Issue
CEO SUMMARY: Many clinical lab administrators have noticed the new activism at the federal Centers for Medicare Medicaid Services (CMS) when it comes to control of establishing prices for clinical laboratory tests. In this exclusive interview, two long-time advocates for the National Inde…
Aetna To Lower Lab Test Prices, New Fees Are Effective on July 1
By Robert Michel | From the Volume XX No. 7 – May 28, 2013 Issue
IN RECENT MONTHS, labs are reporting the receipt of letters from Aetna, Inc., announcing that it will pay dramatically less than Medicare prices for many key lab tests. Aetna said that these lower prices will take effect on July 1, 2013. Three examples illustrate the deep fee cuts t…
Mass Spectrometry Is Finding Larger Role in Clinical Labs
By Joseph Burns | From the Volume XX No. 4 – March 25, 2013 Issue
CEO SUMMARY: Mass spectrometry is a diagnostic technology that is transforming clinical labs and improving care at a rapid pace. The current generation of instruments is capable of supporting a faster time-to-answer and provides improved accuracy and specificity over many existing methods…
LifeLabs, Gamma-Dynacare, Sonic Healthcare, Brigham & Women’s Hospital, Massachusetts General Hospital
By Robert Michel | From the Volume XIX No. 5 – April 2, 2012 Issue
LIFELABS QUEBEC TO BE ACQUIRED BY GAMMA-DYNACARE LAST WEEK, IT WAS ANNOUNCED that Gamma-Dynacare Medical Laboratories had signed a definitive agreement with LifeLabs Limited Partnership to purchase LifeLabs Quebec. Both par…
Payer Trend in New Hampshire Is to Engage Lab Patients
By Robert Michel | From the Volume XIX No. 5 – April 2, 2012 Issue
CEO SUMMARY: A health insurer’s two-year-old effort to have patients choose low-cost laboratory testing options is causing patients to shift their lab work away from New Hampshire’s hospitals and instead use Quest Diagnostics, LabCorp, and ConVerge (a commercial lab company). This new…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized